53 results about "Spondylitis" patented technology

The invention relates to the technical field of traditional Chinese medicines, in particular to a traditional Chinese medicine composition for relieving pain, promoting blood circulation, diminishing swelling and removing blood stasis, application thereof and a blood stasis dispersing and pain relieving patch. The invention provides a traditional Chinese medicine composition for relieving pain, activating blood, diminishing swelling and removing stasis. The traditional Chinese medicine composition comprises the following components: lycopodium clavatum, radix clematidis, asarum, gentiana macrophylla, radix angelicae, rheum officinale, notopterygium root, roasted herba epimedii, radix achyranthis bidentatae, peach kernel, radix angelicae pubescentis, vinegar-processed rhizoma corydalis, vinegar-processed rhizoma cyperi, moutan bark, prepared kusnezoff monkshood root, prepared monkshood, vinegar-processed frankincense, Sinkiang lithospermum, vinegar-processed myrrh and sanguisorba officinalis. The blood stasis dispersing and pain relieving patch has the advantages of being good in curative effect, quick in effect taking, convenient to use, safe and reliable, can be used for treating traumatic injuries and pain caused by cervical spondylosis, scapulohumeral periarthritis, lumbar disc herniation, lumbar vertebrae hyperosteogeny, spinal stenosis, sciatica, ankylosing spondylitis, arthritis and other diseases, and can achieve the effect of treating both symptoms and root causes.

The utility model discloses ankylosing spondylitis spine measuring device relates to medical instrument technical field. Ankylosing spondylitis spine measuring device includes head hoop, pointer, base, scale ring. Head hoop is sleeved in the head of patient, and pointer is arranged on head hoop, and base is arranged on the body of patient, and scale ring is installed on base and is encircled in the circumferential side of the head of patient, and the scale ring is equipped with the scale of degree, the utility model provides ankylosing spondylitis spine measuring device, when using, first, the base is installed on the torso of patient, to make scale encircle and be equipped with in the circumferential side of the head of patient, and then the head hoop is sleeved on the head of patient, at this moment, the rotation of the head of patient is directed again, to make the pointer on head hoop rotate relative to scale, and then the rotation angle of atlas axis of patient is measured, to make the accurate judgement of the body condition of patient for doctor, and the accurate formulation of treatment scheme of patient for doctor is convenient, and the treatment effect of patient is improved.

The present invention discloses a method for constructing an animal model of ankylosing spondylitis and chronic enteritis. By using proteoglycan PG immune induction and sodium dextran sulfate chemical induction methods, an animal model is established that simulates the coexistence of ankylosing spondylitis and chronic enteritis in terms of symptoms, imaging changes, and pathological characteristics. The model mice exhibit imaging changes similar to those of human ankylosing spondylitis, such as sacroiliac joint bone erosion and sclerosis, narrowing and roughening of the joint space, and worm-eaten changes. Furthermore, they exhibit pathological changes similar to those of human chronic enteritis, such as intestinal epithelial cell destruction, glandular disorder, crypt structure destruction, goblet cell reduction, and inflammatory cell infiltration. This model can be used to study the interaction mechanism between the two diseases, explore new therapeutic targets, and help evaluate the potential application of new drugs in the treatment of ankylosing spondylitis and chronic enteritis, providing an important tool for mechanism research and drug development of such co-morbidities.

The utility model relates to the field of auxiliary devices, and discloses an ankylosing spondylitis auxiliary exercise device which comprises a seat plate, a long plate is hinged to the rear end of the seat plate, a waist protection massage assembly is arranged at the top end of the long plate, the waist protection massage assembly comprises a connecting plate, a sliding rail is arranged on the front surface of the connecting plate, and the sliding rail is connected with the long plate. A plurality of sets of supporting plates are slidably connected to the inner wall of the sliding rail, the multiple sets of supporting plates are symmetrically arranged with the center line of the connecting plate as the symmetry axis, a fixing plate is fixedly connected to the front surfaces of the supporting plates, a backup plate is fixedly connected to the top end of the connecting plate, and a neck protection block is slidably arranged on the front surface of the backup plate. According to the device, through cooperation of the waist protection pressing assembly, the neck protection block, the motor and the first electric push rod, the waist of a patient is massaged in the exercising process and during rest of the patient, the pressure of the waist is reduced, the pain of the waist after exercising is relieved, and the practicability of the device is improved.

The present invention provides an antibody comprising citrulline epitope or a binding fragment thereof for use in the treatment or prevention of a disease associated with release of an extracellular trap from a cell, such as a neutrophil extracellular trap (NET)-associated disease (NET-associated disease) or an eosinophil extracellular trap (EET)-associated disease (EET-associated disease), the method comprises administering at least one dose of an antibody at a specific concentration. The present invention also provides these methods themselves. NET related diseases include systemic lupus erythematosus (SLE), lupus, septicemia, vasculitis, inflammatory arthritis, rheumatoid arthritis and osteoarthritis, psoriasis, Alzheimer's disease, autoimmune hepatitis, juvenile idiopathic arthritis, myositis (polymyositis and dermatomyositis), sicca syndrome, antiphospholipid syndrome, Behcet's disease, spondylitis, spondyloarthropathy, multi-system atrophy, and the like. Parkinson's disease, Lewy body dementia, asthma, allergic rhinovirus aggravated asthma, allergic asthma, acute respiratory distress syndrome, cystic fibrosis, fibrosis and idiopathic pulmonary fibrosis, heart failure, atherosclerosis, dry eye disease, uveitis, non-granulogenic uveitis, granulogenic uveitis, dermatitis, atopic dermatitis, COPD, bronchitis, and the like. Or other NET-related diseases, such as wound healing in diabetic patients, cancer, cancer metastasis, and transplanted organ health in vivo or in vitro. The invention also provides a pharmaceutical composition and a method for treating or preventing NET related diseases. Such as SLE, lupus, sepsis, vasculitis, inflammatory arthritis, rheumatoid arthritis and osteoarthritis, psoriasis, Alzheimer's disease, autoimmune hepatitis, juvenile idiopathic arthritis, myositis (polymyositis and dermatomyositis), sicca syndrome, antiphospholipid syndrome, Behcet's disease, spondylitis, spondyloarthropathy, multi-system atrophy, Parkinson's disease, Lewy body dementia, asthma, and the like. Allergic rhinovirus aggravated asthma, allergic asthma, acute respiratory distress syndrome, cystic fibrosis, fibrosis and idiopathic pulmonary fibrosis, heart failure, atherosclerosis, dry eye disease, uveitis, non-granulometric uveitis, granulometric uveitis, dermatitis, atopic dermatitis, COPD, bronchitis, thrombotic disease, cardiovascular disease, and the like. Or other NET-related diseases, such as wound healing in diabetic patients, cancer, cancer metastasis, and transplanted organ health in vivo or in vitro. The EET-related diseases include eosinophilic granulocyte diseases or conditions, such as eosinophilic granulocyte diseases or conditions of skin; a respiratory eosinophilic granulocyte disease or condition; gastrointestinal eosinophilic cell diseases or disorders; allergic diseases or conditions; or worm, fungus, virus or bacterial infection.

The invention discloses a traditional Chinese medicine composition and application thereof in preparation of a medicine for treating ankylosing spondylitis, and belongs to the technical field of medicines. The traditional Chinese medicine composition is prepared from the following raw materials in parts by mass: 5 to 10 parts of myrrh, 8 to 15 parts of rhizoma drynariae, 8 to 15 parts of fructus lycii, 8 to 15 parts of herba epimedii, 8 to 15 parts of radix achyranthis bidentatae, 2 to 6 parts of rhizoma galangae, 8 to 15 parts of fructus forsythiae and 10 to 15 parts of radix astragali seu hedysari. Animal experiments verify that the traditional Chinese medicine composition can remarkably inhibit inflammatory response and bone destruction by regulating T cell immune balance, has good pharmacological activity and safety for treating ankylosing spondylitis, and provides a scientific basis and an innovative application approach for research and development of new traditional Chinese medicines for treating ankylosing spondylitis.

The invention relates to a traditional Chinese medicine composition for treating ankylosing spondylitis, a medicine and a preparation method, and relates to the technical field of traditional Chinese medicines. The invention provides a traditional Chinese medicine composition for treating ankylosing spondylitis. The traditional Chinese medicine composition is prepared from the following raw materials: garden balsam stem, herb of Chinese rabdosia, spina gleditsiae, pangolin scales, camellia oleifera, radix angelicae, sargentgloryvine stem, folium artemisiae argyi, herba asari, leech, ficus microcarpa, semiliquidambar cathayensis, radix gleditsiae, sarcandra glabra, fructus liquidambaris and senecio scandens. The traditional Chinese medicine composition has the effects of dredging tendons and activating blood circulation, can deeply permeate into the body of a patient, enables swollen and calcified muscles and bones to recover to be normal, enables the skin color of a diseased region to recover to be normal, has a very good treatment effect on ankylosing spondylitis, is a neutral medicine, can be accepted by wet, cold and damp-heat constitutions, and is free of toxic and side effects. And the method has wide acceptability.

The disclosure herein provides substituted 6-imidazopyridazine compounds, and pharmaceutical compositions thereof, for use in the modulation of IL-17A. These compounds are useful in the treatment of inflammatory conditions such as psoriasis, psoriatic arthritis or ankylosing spondylitis.

The invention discloses an ankylosing spondylitis detection device, relates to the technical field of spondylitis detection equipment, and provides the following scheme that the ankylosing spondylitis detection device comprises a pillow-wall distance detection device, and a pillow-wall distance detection auxiliary support is arranged on the front side of the upper surface of the pillow-wall distance detection device; the rear side of the upper surface of the pillow-wall distance detection device is provided with a ground-pointing distance detection device, and a jaw-handle distance and thoracic activity detection device is arranged above the pillow-wall distance detection auxiliary support. According to the technical scheme, by arranging the comprehensive detection mechanism for the ankylosing spondylitis, multiple items such as pillow-wall distance detection, jaw-handle distance detection, finger-ground distance detection, thoracic activity detection and Schober detection are integrated, so that a patient can complete the detection operation of multiple detection items in one mechanism, and the detection efficiency is improved. And meanwhile, all detection data can be quickly and accurately displayed at one time, so that the detection time of the patient is shortened, and the body data of the patient can be more intuitively observed.

To provide an etanercept pharmaceutical composition, a method for producing the same, and a method for treating a patient having rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, or psoriasis.SOLUTION: A pharmaceutical composition comprising 75mM to 150mM NaCl, 5mM to 100mM arginine, 0.5% to 2% (w / v) sucrose, and 40mg to 100mg / mL etanercept, wherein the composition comprises 2. less than 0mM total additional buffer, and wherein the pH of the composition is between 6.1 and 6.5.SELECTED DRAWING: Figure 1

The application relates to the field of biotechnology, and particularly relates to the application of carnosic acid as an ERAP1 inhibitor in the preparation of a drug for treating ankylosing spondylitis of an autoimmune disease. The application first discovers that a monomer compound carnosic acid from a natural product source can be used as an ERAP1 direct targeting inhibitor in the preparation of a drug for regulating an endogenous antigen processing and presentation pathway and ankylosing spondylitis of a related autoimmune disease. The carnosic acid can be specifically combined in an ERAP1 active site through direct high-activity targeting, and the carnosic acid inhibits the activity of the ERAP1, is the highest in activity in the world, and has high selectivity in targeting the ERAP1 active site. The carnosic acid reverses the ankylosing spondylitis molecular pathological phenotypes caused by abnormal ERAP1 activity, including endoplasmic reticulum stress, reducing an extra amount of HLA-B27 molecules displayed on a cell surface, reducing the proportion of the HLA-B27 molecules incorrectly assembled on the cell surface, and maintaining normal antigen presentation functions.

The present invention includes compositions and methods for treating diseases or disorders associated with pathological calcification or pathological ossification. In certain embodiments, the diseases or disorders are selected from the group consisting of Generalized Arterial Calcification of Infancy (GACI), Idiopathic Infantile Arterial Calcification (IIAC), Ossification of the Posterior Longitudinal Ligament (OPLL), hypophosphatemic rickets, osteoarthritis, calcification of atherosclerotic plaques, PXE, hereditary and non-hereditary forms of osteoarthritis, ankylosing spondylitis, hardening of the arteries occurring with aging, calciphylaxis resulting from end stage renal disease and progeria.

The present invention discloses a method for constructing a spontaneous ankylosing spondylitis model and its application. The ankylosing spondylitis model is a non-human animal model, and the spontaneous ankylosing spondylitis non-human animal model is constructed by expressing mutant BMP9 protein. The present invention also provides a method for identifying a therapeutic agent for treating ankylosing spondylitis using the spontaneous ankylosing spondylitis non-human animal model. The present invention further provides an application of the spontaneous ankylosing spondylitis non-human animal model in evaluating the efficacy of a therapeutic agent in treating or preventing ankylosing spondylitis.

The invention relates to the technical field of body conditioning medicines, in particular to a medicine formula for conditioning a body movement system and a preparation process of the medicine formula. Comprising a main material and an auxiliary material, the main material is prepared by mixing the following raw materials by weight: 15-24 g of white peony root, 2-8 g of licorice, 4-12 g of achyranthes bidentata, 2-8 g of safflower, 5-15 g of dogwood, 5-12 g of prepared rehmannia root, 5-15 g of eucommia ulmoides, 2-10 g of fennel, 4-15 g of fructus aurantii and 15-25 g of folium artemisiae argyi; the auxiliary material is prepared by mixing the following raw materials by weight: 3-7 g of coix seed powder, 1-3 g of small red bean powder, 1-3 g of pea powder, 1-3 g of buckwheat powder, 1-3 g of Chinese yam powder, 1-3 g of soybean powder, 1-3 g of hyacinth bean powder, 8-12 g of Chinese wolfberry and 8-12 g of red dates. The formula has the beneficial effects that the formula is scientifically prepared, the nutrition is balanced, and diseases such as cervical spondylosis, chest, neck, waist and leg pains (chest, neck, waist and legs), protrusion of intervertebral disc, ankylosing spondylitis, arthritis, tennis elbow, rheumatic arthritis, femoral head necrosis, numbness of limbs, arthralgia, synovitis, knee effusion, meniscus injury, hyperostosis, sciatica and varicosity can be conditioned.

The present application discloses a remote data acquisition system and method for early screening of ankylosing spondylitis. The system includes: a basic information acquisition unit, a posture information acquisition unit, a thoracic expansion information acquisition unit, and an information extraction unit. The basic information acquisition unit is used to receive the symptom description information of the user; the posture information acquisition unit is used to acquire the continuous posture information of the user; the thoracic expansion information acquisition unit is used to acquire the thoracic expansion information of the user during the breathing process; the information extraction unit is used to extract the corresponding symptom description data, posture data, and thoracic expansion data of the user based on the symptom description information, the posture information, and the thoracic expansion information respectively, and can accurately obtain the user's state information in multiple dimensions, providing accurate data support for early screening by doctors.

The present application discloses a method and apparatus for processing activity time data of ankylosing spondylitis patients monitored by a wearable device. The method comprises: obtaining initial time data corresponding to various activity behaviors of ankylosing spondylitis users by using a wearable device, wherein the activity behaviors include sedentary behavior, sleeping behavior, low-intensity physical activity behavior, and medium-to-high-intensity physical activity behavior; determining comparative features between the various activity behaviors based on the initial time data; constructing a sleep quality regression classification model based on the comparative features; and determining a target time allocation scheme corresponding to each of the activity behaviors when the probability of the ankylosing spondylitis user having good sleep quality is maximized based on the sleep quality regression classification model. The method can allocate personalized target time data that can improve the sleep quality of ankylosing spondylitis users based on the initial time data of various types of activity behaviors of the ankylosing spondylitis users.

The invention belongs to the technical field of medical apparatus and instruments, and provides a spine movement assist device suitable for patients with ankylosing spondylitis aiming at the problems that an existing device for relieving the ankylosing spondylitis disease is poor in use effect and single in function, and the spine movement assist device comprises a back relieving mechanism, a neck movement mechanism and a lower limb movement mechanism; the upper body of a patient is clamped and fixed through the back relieving mechanism, so that the back of the patient is massaged while medicine is applied to the back of the patient; the patient can perform rehabilitation exercise through the neck movement mechanism and the lower limb movement mechanism so as to improve the spine movement range of the patient.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for treating ankylosing spondylitis and a preparation method thereof. The traditional Chinese medicine is prepared from the following raw materials: 6-18 g of fructus psoraleae, 6-20 g of herba epimedii, 3-15 g of radix aconiti lateralis preparata, 6-20 g of rhizoma drynariae, 9-18 g of radix achyranthis bidentatae, 12-24 g of dipsacus root, 6-12 g of radix clematidis, 10-30 g of garden balsam stem, 10-30 g of lycopodium clavatum, 9-15 g of radix paeoniae rubra, 6-12 g of native copper, 3-9 g of Chinese polyphaga, 6-12 g of roasted rhubarb, 6-15 g of notopterygium root, 6-15 g of radix angelicae pubescentis, 6-12 g of radix saposhnikoviae, 3-9 g of ephedra, 9-15 g of radix paeoniae alba, 6- The traditional Chinese medicine composition is prepared by adding and reducing cassia twig, Chinese herbaceous peony and rhizoma anemarrhenae decoction which are Jingui to be a little, the inflammatory response, bone destruction and pain symptoms of ankylosing spondylitis are accurately improved through the synergistic effect of multiple target points, and meanwhile, the preparation process is standardized to ensure the stable medicine effect.

The invention relates to the technical field of traditional Chinese medicine, and particularly discloses a compound preparation for treating rheumatoid arthritis and a preparation method thereof.The preparation is prepared from salvia miltiorrhiza, rhodiola rosea, semen cuscutae, asparagus cochinchinensis, fritillaria pallidiflora, curcuma zedoary and radix clematidis through solvent extraction, impurity removal, concentration or drying. The traditional Chinese medicine composition and medically acceptable auxiliary materials are prepared into granules, oral preparations, pills, capsules, tablets and the like. The compound preparation has the effects of expelling wind, removing cold, removing dampness, tonifying qi, nourishing blood, nourishing liver-kidney deficiency, promoting blood circulation, removing blood stasis, diminishing swelling, eliminating phlegm, dredging collaterals and relieving pain. The traditional Chinese medicine composition is used for treating rheumatoid arthritis, ankylosing spondylitis, chronic arthritis and rheumatic sciatica. The compound preparation disclosed by the invention can be used for effectively relieving joint tissue injury and inflammation of a Fisher adjuvant induced arthritis mouse, inhibiting the activation of DC and macrophages in a fossa lymph node and a spleen and the secretion of IL-6 and TNF-a, reducing the number of Th1 and Th17, increasing the number of Treg cells, increasing the proportion of Th2 / Th1 cells and recovering the immune balance of CD4 cells, and has a treatment effect.

1. The name of this design product: Spinal Mobility Measuring Ruler (Ankylosing Spondylitis). 2. Purpose of this design product: used for measuring spinal mobility. 3. The key point of the design of this product lies in its shape. 4. The picture or photo that best illustrates the design points: three-dimensional picture.

The Tibetan medicine fifty-six agate pill is mainly prepared from fifty-six medicinal materials including zota, pearls, agate, fructus chebulae, semen myristicae, tabasheer and the like, and has the effects of restoring consciousness, inducing resuscitation, easing mental tranquility, clearing and activating the channels and collaterals, enriching blood, tonifying qi, building the body, prolonging life and enhancing the immunity of the organism. The traditional Chinese medicine composition is used for treating red pulse, black pulse and white pulse diseases caused by the longishi disease and three-cause (longishi, red pulse and bacon) imbalance, and cardiovascular and cerebrovascular diseases and nervous system diseases. The traditional Chinese medicine composition is suitable for diseases such as heart disease, Parkinson's disease, Alzheimer's disease, sleep disorder, hypertension, Meniere's syndrome, gastrointestinal diseases, stroke, paralysis, hemiplegia, ankylosing spondylitis, epilepsy, cerebral hemorrhage, cerebral concussion and gradual freezing; and various intractable diseases such as heavy metal detoxification are treated.

According to the multi-label automatic diagnosis and evaluation system and method for ankylosing spondylitis, pelvic X-ray film images and clinical data are combined, automatic diagnosis of ankylosing spondylitis is achieved through a multi-label classification model, and the severity degree of injury of sacroiliac joints and hip joints is evaluated. The system adopts a prior attention mechanism, can automatically focus a key area in an image, and further improves the diagnosis efficiency. Experimental results show that the system still has relatively high diagnosis accuracy in an environment with limited resources, and can be comparable with diagnosis results of experienced doctors. The multi-label classification model with the priori attention mechanism provided by the invention provides a promising and cost-effective tool for diagnosis and evaluation of ankylosing spondylitis, and has important practical application value.

The invention provides a D-shaped hollow cylindrical thoracolumbar vertebra side wall interbody fusion cage for a rachitis operation, which belongs to the technical field of medical instruments for spine surgery, is an integrally formed rigid structure without movable parts, is a D-shaped hollow cylindrical body on the whole, and comprises a fusion cage cylindrical body with a fixed height, the cross section of a main body is D-shaped, and the cross section of the main body is L-shaped; the upper end face and the lower end face of an arc-shaped side wall and a plane side wall are enclosed by the upper end face and the lower end face; the cylindrical hollow cavity penetrates through the fusion cage cylindrical body in the axial direction, and the micron-sized rough textures are arranged on the outer surfaces of the arc-shaped side wall and the plane side wall. Anatomical matching with the lateral bone surface of the vertebral body is achieved through the D-shaped section, and load transmission and stress distribution are fundamentally improved in combination with large-area contact between the planar side wall and the end plate. Unprecedented initial stability is provided for the fusion cage in infectious loose bone, and the risks of displacement, sedimentation and disengagement are remarkably reduced.

The invention provides a method for inducing ankylosing spondylitis synovial fibroblast osteogenesis in vitro, and belongs to the technical field of cell culture, the ankylosing spondylitis hip joint synovial fibroblast is induced in vitro by using 100ng / mL of tumor necrosis factor-alpha (TNF-alpha) and 100ng / mL of bone morphogenetic protein 2 (BMP-2), and the ankylosing spondylitis hip joint synovial fibroblast can be converted into osteoblasts 12 days after induction. The ankylosing spondylitis synovial fibroblast osteogenesis is specifically induced, the interference of non-target cells is reduced, and the accuracy and reliability of the experiment are improved; the method disclosed by the invention is simple, strong in operability and good in controllability, lays a foundation for research on pathogenesis of new bone formation of ankylosing spondylitis, can greatly shorten the experimental period, and has better application prospects compared with traditional BMP-2 and TGF-beta induced fibroblasts. The osteogenesis model constructed by the method is closer to an osteogenesis mechanism of ankylosing spondylitis and is higher in conversion efficiency.

The invention discloses an ankylosing spondylitis spinal injury severity prediction model construction method and system, and the method comprises the following steps: S1, carrying out the data collection of an ankylosing spondylitis patient, the data including epidemiological data, clinical phenotypes and laboratory detection indexes; s2, layering the risk layers, and dividing a spinal injury severity high-risk group and a spinal injury severity low-risk group by taking mSASSS = 25 as a threshold value; s3, eliminating radiology dependent variables through logistic regression analysis, and screening out independent predictive factors; s4, constructing a spinal injury severity prediction column graph model based on the independent prediction factors; s5, vertically mapping the measured value of each index of the patient to a scale axis corresponding to the column diagram to obtain a single score; and after the total score of the six items is accumulated, positioning is performed on a risk coordinate axis to obtain a predicted risk probability. The method improves the disease prediction capability, is high in clinical universality, is convenient and efficient to operate, and has a treatment intervention guidance value.

The invention provides an ankylosing spondylitis condition reminding method based on a large model, electronic equipment and a storage medium, and relates to the technical field of artificial intelligence and computers. According to the implementation scheme, a first illness state reminding triggering reason is determined based on follow-up visit data of a first ankylosing spondylitis patient; determining a first reminding text based on patient characteristics of the first ankylosing spondylitis patient and illness state index data in follow-up visit data corresponding to the first illness state reminding triggering reason; taking the first illness state reminding trigger reason and the patient characteristics of the first ankylosing spondylitis patient as input samples, taking the first reminding text as an output sample, constructing a first training sample, and training a large language model; on the basis of follow-up visit data of a second ankylosing spondylitis patient, under the condition that a second illness state reminding trigger reason of the second ankylosing spondylitis patient is obtained, the second illness state reminding trigger reason and patient features of the second ankylosing spondylitis patient are input into the large language model, and a second reminding text is obtained.

The invention discloses a data processing method and device for monitoring activity time of an ankylosing spondylitis patient by using a wearable device, and the method comprises the steps: obtaining initial time data corresponding to each activity behavior of the ankylosing spondylitis patient by using the wearable device, the activity behaviors comprise a sedentariness behavior, a sleep behavior, a low-intensity physical activity behavior and a medium-high-intensity physical activity behavior; based on the initial time data, determining comparison characteristics among the activity behaviors; constructing a sleep quality regression classification model based on the comparison features; based on the sleep quality regression classification model, determining a target time allocation scheme corresponding to each activity behavior when the probability that the sleep quality of the ankylosing spondylitis user is good is maximum, the personalized target time data capable of improving the sleep quality can be allocated to the ankylosing spondylitis user based on the initial time data of various types of activity behaviors of the ankylosing spondylitis user.

The invention relates to application of an SOX5 inhibitor in preparation of a medicine for preventing and treating ankylosing spondylitis, and belongs to the technical field of biological medicine. The invention provides application of an SOX5 inhibitor in preparation of a medicine for preventing and treating ankylosing spondylitis. The SOX5 inhibitor inhibits SOX5 gene and / or protein expression. The SOX5 for inhibiting the starting and ending point stromal cells can accurately block the effect of mechanical stress on the ankylosing spondylitis starting and ending point disease, and meanwhile, interference on physiological mechanical stress signal transduction in normal tissues such as osteogenesis, cartilage and muscle is avoided. Through targeted inhibition of SOX5, formation of pathogenic cells (SDC1 + tendon sheath stromal cells) is reduced, transduction of mechanical signals to inflammation signals is blocked, and a more thorough and lasting treatment effect is achieved. By detecting the expression level of SOX5 in start-end point tissues, the kit is used for early diagnosis of AS start-end point diseases, assessment of disease activity and prediction of SOX5 targeted therapy response of patients.

The application discloses a kind of cross-modal spinal structure damage quantification method and system, belong to medical image processing and depth learning auxiliary evaluation technical field.The method obtains the median sagittal CT image and standard lumbar lateral X-ray film of the same examinee, after standardization pretreatment, respectively input the double-flow Swin Transformer feature extraction network with same structure but independent weight;Again through bidirectional cross-modal attention module, with one side modal feature through bottleneck type gate network generates channel level attention weight, act on opposite side modal feature and introduce residual connection;After the features of bidirectional calibration are spliced, input multi-head MLP classifier, output the structural damage severity classification (Grade 0 / 1 / 2) of four corner points (front upper, front lower, back upper, back lower) of vertebral unit.The self-excitation logic of general attention is transformed into cross-modal mutual excitation logic in the application, explicitly uses CT tomographic structure prior to suppress X-ray projection artifact, and uses X-ray overall topological constraint CT local feature, realizes AUC=0.9128, QWK=0.7879 on internal independent test set, and the grade consistency is significantly better than simple feature splicing and primary clinician, provides objective and efficient quantification tool for the standardization follow-up of ankylosing spondylitis and other spinal joint disease structural damage.

The invention belongs to the technical field of biological detection, and discloses a marker combination for diagnosing ankylosing spondylitis and application thereof, and the key point of the technical scheme is that the marker combination is composed of TGF [beta] 3, BMP2, TNF [alpha] and sTNFR1. The invention also discloses application of the marker combination in preparation of a reagent for diagnosing ankylosing spondylitis. A detection sample of the reagent is serum, and the reagent is used for detecting the expression quantity and / or content of the marker combination. The marker combination provided by the invention has higher prediction value on an early pathological osteogenesis stage; the inflammation-dominated AS patient and the osteogenesis-dominated AS patient can be distinguished through combined detection; the detection system can be realized based on serum samples and is convenient to popularize and apply.